Mfg-e8 and uses thereof

A technology of MFG-E8 and hmfg-e8, applied in the field of MFG-E8 and its application

Inactive Publication Date: 2014-08-13
THE FEINSTEIN INST FOR MEDICAL RES
View PDF8 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, one obstacle preventing the development of MFG-E8 as a therapeutic agent for patients is the potential immunogenicity of animal proteins in humans

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mfg-e8 and uses thereof
  • Mfg-e8 and uses thereof
  • Mfg-e8 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0097] Embodiment 1. The treatment of recombinant human MFG-E8 and sepsis

[0098] Materials and methods

[0099] Expression of recombinant human MFG-E8: Amplify the plasmid template containing human MFG-E8 cDNA by polymerase chain reaction to obtain a 1095bp fragment encoding the mature region of human MFG-E8 (364 amino acids, R24-R387, SwissProt#:Q08431) (SEQ ID NO: 3). The open reading frame was cloned into the SalI and NotI sites of the pET-28a(+) vector (Novagen, Madison, WI), downstream of the phage T7 RNA polymerase promoter. The final protein product contains 6 histidines fused to the N-terminus of human MFG-E8. The plasmid was transformed into E. coli BL21(DE3) cells. Cells were grown overnight at 37°C in 2YT medium (Invitrogen) containing kanamycin. rhMFG-E8 protein production was induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) to a final concentration of 1.0 mM, and the cells were grown for an additional 5 h at 25°C. Cells were harvested b...

Embodiment II

[0119] Embodiment II. Use recombinant human MFG-E8 to treat cerebral ischemia

[0120] Materials and methods

[0121] Experimental Animals: Male Sprague-Dawley rats (300-350 g) purchased from Charles River Laboratories (Wilmington, MA) were used in this study. Rats were housed under standard conditions (room temperature, 22°C, 12 / 12-h light / dark cycle) with regular access to standard Purina rat chow and water. Animals were acclimated to these conditions for at least 5 days before being used in experiments. All animal experiments were performed in accordance with the National Institutes of Health guidelines for laboratory animals. The protocol was approved by the Institutional Animal Use and Care Committee (IACUC) of the Feinstein Institute for Medical Research.

[0122]Cerebral ischemia model: Prior to induction of cerebral ischemia, rats were fasted overnight but had access to water ad libitum. Permanent focal cerebral ischemia was induced by middle cerebral artery occlus...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Methods of treating cerebral ischemia by using milk fat globule epidermal growth factor-factor VIII (MFG-E8) are disclosed, as are recombinant human MFG-E8 and uses thereof in pharmaceutical compositions, products and methods for treating inflammation and organ injury after ischemia / reperfusion, sepsis, and lung injury.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application No. 61 / 480,031, filed April 28, 2011, the contents of which are hereby incorporated by reference in their entirety. [0003] Statement of Government Funding [0004] This invention was made with Government support under Grant No. GM057468 awarded by the National Institutes of Health. The government has certain rights in this invention. Background of the invention [0005] Throughout this application, various publications are referred to in parentheses. Full citations for these references can be found at the end of the specification. The disclosures of these publications in their entireties are incorporated by reference into this application to more fully describe the field to which this invention pertains. [0006] Inflammation and apoptosis play crucial roles in the evolution of cerebral infarction after ischemic injury. Following necrotic cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18
CPCA61K38/1709A61K38/1808A61P29/00A61P9/10
Inventor 王平
Owner THE FEINSTEIN INST FOR MEDICAL RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap